Perspective Confidentiality Disclosure Reliability Courtesy
Natural orifice transluminal endoscopic surgery or NOTES refers to the conduct of minimally invasive surgery through natural orifices (like the mouth or the vagina or the nose).
Filed under: Management, Treatment, Uncategorized | Tagged: NOTES, radical prosatectomy, minimally invasive | Leave a Comment »
Dr. David Agus — a cancer researcher at the University of Southern California’s Keck School of Medicine — must be feeling happier today, thanks to one of his former patients.
Filed under: Uncategorized | Tagged: Agus, Redstone, donation | Leave a Comment »
There’s a new media story circulating today about “important new research” related to the impact of eating broccoli on risk for prostate cancer.
Filed under: Uncategorized | Tagged: broccoli, sulforaphane | 2 Comments »
We have mentioned Winter Vinecki once before on this web site, but newer readers may never have come across this singular young lady. If you haven’t heard her name before, you have now … and you will be hearing it some more in the future.
Filed under: Uncategorized | Leave a Comment »
For years, some clinicians have been telling their patients to use a 5α-reductase inhibitors (5-ARIs) like finasteride or dutasteride as a form of “bridge” therapy to extend their periods of time off primary hormone therapy while being treated with intermittent hormone therapy or IHT.
Filed under: Uncategorized | Tagged: 5-ARI, finasteride, IHT, intermiottent hormone therapy | 5 Comments »
A media release from the Uniformed Services University of the Health Sciences last week announced the development of a highly specific assay for the detection of ERG oncoprotein. The assay is based on the development of an anti-ERG monoclonal antibody that appears to be capable of detecting the presence of ERG oncoprotein with > 99 percent accuracy.
Filed under: Uncategorized | Tagged: test, ERG, monoclonal antibody, oncoprotein | Leave a Comment »
Every so often a wise and experienced clinician scolds us kindly for our tendency to think that every medical problem — however minor or however serious — requires urgent and aggressive action. An article by Albert Lim, MD, in yesterday’s New York Times, is perhaps relevant to Planet Prostate Cancer.
Filed under: Uncategorized | Comments Off
New data from a research team at the Institute for Cancer Research in the UK suggest that — in men and women with a faulty BRCA2 gene — the development of breast cancer and prostate cancer follows a similar pathway.
Filed under: Uncategorized | Tagged: BRCA2, gene | Leave a Comment »
OncoGenex has initiated the first of two Phase III trials of custirsen sodium (OGX-011) in the treatment of men with metastatic castrate-resistant prostate cancer (mCPRC).
Filed under: Drugs in development, Uncategorized | Tagged: castration-resistant, custirsen, mCRPC, OGX-011, OncoGenex | Leave a Comment »
At a quick glance one could get the idea from a new study that men of African ethnicity in the Caribbean were fundamentally more likely to die of prostate cancer than men of African ethnicity in the USA. However, a more careful reading of the study data suggests that this may not, really, be the case.
Filed under: Uncategorized | 2 Comments »
It has been getting increasingly clear that elevated doses of radiation to the prostate result in better prostate cancer-specific survival for men treated with first-line radiotherapy for localized prostate cancer.
Filed under: Uncategorized | 8 Comments »
Back in 2008 we first mentioned the initiation of clinical trials of a drug called Apoptone or HE3235 in men with hormone-refractory prostate cancer. Data on the development of Apoptone was another item on the agenda at the annual meeting of the American Society of Clinical Oncology (ASCO) earlier this week.
Filed under: Drugs in development, Uncategorized | Tagged: Apoptone, castration-resistant, HE3235, hormone refractory | Leave a Comment »
According to a media release from the Prostate Cancer Foundation yesterday, research at the University of Michigan Comprehensive Cancer Center suggests that the RAF oncogene that drives fatal forms of melanoma (an aggressive type of skin cancer) may also drive aggressive forms of prostate cancer.
Filed under: Diagnosis, Drugs in development, Risk, Uncategorized | Tagged: fusion, gene, oncogene, RAF | 5 Comments »
The Prostate Cancer Foundation (PCF) has announced plans for a National Proactive Surveillance Network (NPSN) designed to reduce overtreatment of prostate cancer patients to better direct resources to those patients with more aggressive, life-threatening varieties of this disease.
Filed under: Uncategorized | Tagged: active surveillance, National Proactive Surveillance Network | 2 Comments »
We note that the second Phase III clinical trial of abiraterone acetate — in asymptomatic or mildly symptomatic patients with metastatic, castration-resistant prostate cancer (mCRPC) who have not had either chemotherapy or ketoconazole therapy — is now fully enrolled (as of last Friday).
Filed under: Drugs in development, Uncategorized | Tagged: abiraterone, trial | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site